Feed

The diagnosis of neuroinfectious diseases, including Tuberculous Meningitis (TBM), viral encephalitis, Human Immunodeficiency Virus (HIV), and post COVID-19 neurological syndromes, remains challenging due to limited surveillance, non-specific symptoms, inadequate laboratory sensitivity, and restricted availability of high-quality CSF or tissue specimens. The critical need for early and precise diagnosis and the development of reliable, validated biomarkers highlight the importance of biospecimen-driven approaches that leverage CSF and other biobanked materials, as evidenced by the emerging literature. This review aims to summarize the need for biobanks, discuss sample preservation and tracking, examine quality control frameworks, and evaluate current advances, translational applications, and ongoing challenges of biobanking in neuroinfectious disease research. We extracted evidence from existing neuroinfection biobanks, reviewed global standards governing bio-specimen preservation and storage, and analyzed studies demonstrating how archived CSF, blood, and brain tissue have enabled pathogen characterization, biomarker discovery, and translational research. Our analysis shows that biobanked specimens have facilitated high-resolution pathogen genotyping, immune profiling, and identification of diagnostic and prognostic biomarkers, such as neuro-filament light chain (NfL) and CSF proteomic signatures. Strengthening biobanking infrastructure, harmonized governance, established FAIR-aligned data systems, and the integration of AI and digital analytics will help accelerate biomarker validation, drive diagnostic innovation, and ultimately improve clinical outcomes for patients worldwide.